磷脂酰肌醇3激酶δ过度活化综合征治疗进展  

Progress in treatment of activated phosphoinositide 3⁃kinaseδsyndrome

作　　者：吴涛 刘文慧 WU Tao;LIU Wenhui(Department of Hematology,The 940th Hospital of Joint Logistics Support Force of the Chinese People’s Liberation Army,Lan-zhou 730050,China)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院血液科,甘肃兰州730050

出　　处：《内科理论与实践》2024年第2期140-143,共4页Journal of Internal Medicine Concepts & Practice

基　　金：甘肃省科技计划项目(21JR7RA015、22YF7FA106)。

摘　　要：磷脂酰肌醇3激酶δ(phosphoinositide 3⁃kinaseδ,PI3Kδ)过度活化综合征(activated phosphoinositide 3⁃kinaseδsyndrome,APDS)于2013年首次报道。APDS是一种PIK3CD基因或PIK3R1基因突变导致的常染色体显性遗传的原发性免疫缺陷病(primary immunodeficiency disease,PID),临床表现为反复呼吸道感染、非肿瘤性淋巴组织增生、自身免疫性疾病及淋巴瘤等。本文详细介绍了APDS治疗方案,除常规针对免疫缺陷治疗外,如抗菌药物预防、免疫球蛋白替代治疗及造血干细胞移植等,还讨论了针对性更强的哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)抑制剂和PI3Kδ抑制剂。Phosphoinositide 3⁃kinaseδ(PI3Kδ)activated phosphoinositide 3⁃kinaseδsyndrome(APDS)was first reported in 2013.APDS is an autosomal dominant primary immunodeficiency disease(PID)caused by mutations in the PIK3CD gene or PIK3R1 gene.The clinical manifestations of APDS are recurrent respiratory tract infection,non⁃neoplastic lymphoid hyperplasia,autoimmune diseases and lymphoma.In this paper,the treatment of APDS is introduced in detail.In addition to conventional treatment for immunodeficiency,treatment such as antimicrobial prophylaxis,immunoglobulin replacement therapy and hematopoietic stem cell transplantation were reviewed,and more specific mammalian target of rapamycin(mTOR)inhibitors and PI3Kδinhibitors were also discussed.

关 键 词：PI3Kδ过度活化综合征 造血干细胞移植 MTOR抑制剂 PI3Kδ抑制剂 

分 类 号：R593.3[医药卫生—内科学] R457.7[医药卫生—临床医学]